Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates its business through three segments: Delivery Devices, Diabetes Direct and Other. The Delivery Devices segment consists of business with the product group's pen systems, pen needles, infusion sets and other injection molded parts that are developed and manufactured by company. The Diabetes Direct segment consists of the sales and direct trade business with various supplies for diabetes care, for example, devices for the self-monitoring of blood glucose levels as well as infusion pumps, accessories and other day-to-day items for diabetics. The Other segment consists of precision-turned parts and real estate not currently in operational use. The company was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.